Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.85 |
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14707898 | 0.92 | MAPT (0.85) | MAPTPOLBRXFP1KDM4EMEN1 | |
| SCHEMBL12285666 | 0.87 | RXFP1 (0.73) | MAPTPOLBRXFP1MEN1ALDH1A1 | |
| SCHEMBL12285491 | 0.84 | RXFP1 (1.00) | MAPTPOLBRXFP1THRBTP53 | |
| SCHEMBL14707901 | 0.79 | MAPT (0.81) | MAPTPOLBRXFP1MEN1ALDH1A1 | |
| SCHEMBL12288667 | 0.78 | RXFP1 (0.70) | MAPTPOLBRXFP1MEN1ALDH1A1 | |
| SCHEMBL12288668 | 0.78 | RXFP1 (0.82) | MAPTPOLBRXFP1THRBTP53 | |
| SCHEMBL12286344 | 0.76 | RXFP1 (0.84) | MAPTPOLBRXFP1MEN1KMT2A | |
| SCHEMBL12287171 | 0.75 | RXFP1 (0.78) | MAPTPOLBRXFP1KDM4EMEN1 | |
| SCHEMBL12668678 | 0.75 | MAPT (0.57) | MAPTRXFP1MEN1ALDH1A1KMT2A | |
| SCHEMBL1895578 | 0.74 | L3MBTL1 (0.75) | POLBKDM4EMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927561-B2 | Pyrimidinedione anti-viral compounds | Kineta, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011133722-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | MAVS, EIF2AK2, DDX5 | MAPT 4165/4885POLB 444/4885RXFP1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.